Biodesix (BDSX)
(Delayed Data from NSDQ)
$1.66 USD
+0.04 (2.47%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.60%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
BDSX 1.66 +0.04(2.47%)
Will BDSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDSX
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
BDSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
Other News for BDSX
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”
Biodesix to Participate in Two Investor Conferences in June
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
Buy Rating Justified by Biodesix’s Market Leadership and Strong Growth Prospects
Biodesix initiated with bullish view at TD Cowen, here's why